Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside by Amato, Angélica Amorim & de Assis Rocha Neves, Francisco
Hindawi Publishing Corporation
PPAR Research




Lessons fromBench and Bedside
Ang´ elica Amorim Amato and Francisco de Assis Rocha Neves
Laborat´ orio de Farmacologia Molecular, Departamento de Ciˆ encias Farmacˆ euticas, Faculdade de Ciˆ encias da Sa´ ude,
Universidade de Bras´ ılia, Campus Universit´ ario Darcy Ribeiro, Bras´ ılia, CEP 70910-900, Brazil
Correspondence should be addressed to Ang´ elica Amorim Amato, angelicamato@unb.br
Received 6 February 2012; Accepted 23 April 2012
Academic Editor: Christopher J. Nicol
Copyright © 2012 A. A. Amato and F. de Assis Rocha Neves. This is an open access article distributed under the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
The incidence of type 2 (T2D) diabetes and other chronic conditions associated with insulin resistance is increasing at an
alarming rate, underscoring the need for eﬀective and safe therapeutic strategies. Peroxisome-proliferator-activated receptor
gamma (PPARγ) has emerged as a critical regulator of glucose homeostasis, lipid homeostasis, and vascular inﬂammation.
Currently marketed drugs targeting this receptor, the thiazolidinediones (TZDs), have proven beneﬁts on insulin resistance and
hyperglycemia associated with T2D. Unfortunately, they have been associated with long-term unfavorable eﬀects on health, such
as weight gain, plasma volume expansion, bone loss, cardiovascular toxicity, and possibly cancer, and these safety concerns have
led to reduced interest for many PPARγ ligands. However, over the last years, data from human genetic studies, animal models,
and studies with ligands have increased our understanding of PPARγ’s actions and provided important insights into how ligand
development strategies could be optimized to increase eﬀectiveness and safety of PPARγ-based therapies.
1.Introduction
Peroxisome-proliferator-activated receptors (PPARs) are
members of the nuclear receptor superfamily that het-
erodimerize with retinoid X receptors (RXRs) to modulate
the transcription of target genes. They are activated by fatty
acids [1] and are thus considered lipid sensors involved
in the transcriptional regulation of energy metabolism [1].
Three isotypes of PPAR have been identiﬁed so far, namely,
PPARα,PP ARβ/δ,andPP ARγ,eachwithadistinctpatternof
tissue distribution and with unique physiological functions
[2]. Brieﬂy, PPARα is found in the liver, kidney, heart, and
muscle and is implicated in the uptake and oxidation of fatty
acids and lipoprotein metabolism. PPARβ/δ is expressed
in most cell types and plays an important role in lipid
metabolism and cell diﬀerentiation and growth. PPARγ
actions are mediated by two isoforms, PPARγ1, which has
a wide tissue expression, and PPARγ2, highly expressed
in adipose tissue and considered the master regulator of
adipocyte diﬀerentiation and function. It is noteworthy that
PPARs are also expressed in macrophages, in which they are
key modulators of the inﬂammatory response [3].
Consistent with their signiﬁcance in metabolism phys-
iology, this subfamily of nuclear receptors is an important
target in metabolic disease. This is evidenced by the fact that
PPARα is the molecular target for the lipid-lowering ﬁbrate
drugs and PPARγ is the target for the insulin-sensitizing
TZDs. In fact, the identiﬁcation of the lipid sensor PPARγ
as a key regulator of glucose metabolism came from the
discovery that TZDs are potent agonists for this receptor [4].
TZDs increase insulin action in diverse animal models of
insulin resistance and also in patients with T2D. However,
the molecular basis of improved insulin sensitivity by
activation of this “pro-obesogenic” receptor is incompletely
understood [5], especially considering that obesity and T2D
do not represent states of PPARγ deﬁciency. Insights from
tissue-speciﬁc animal knockout models of PPARγ and also
from ligand studies suggest there are at least two plausible
mechanisms [6]. Activation of PPARγ in adipose tissue
improves its ability to store lipids, reducing lipotoxicity2 PPAR Research
in muscle and liver. Also, PPARγ agonists modulate the
synthesis and release of a number of signaling molecules
fromtheadipocytesandmacrophagesresidentintheadipose
tissue, with signiﬁcant metabolic eﬀects in other tissues [2].
There is also evidence that PPARγ activation outside the
adipose tissue is important for the insulin-sensitizing actions
of TZDs [7–9].
Despite their metabolic beneﬁts, TZDs may have clini-
callysigniﬁcantadverseeﬀects,suchasincreasedbodyweight
[6, 10], ﬂuid retention [11], increased risk of heart failure
[11], bone loss [12], increased risk of myocardial infarction
[13], and a potential link with bladder cancer [14, 15].
Because of the concerns on cardiovascular toxicity, rosiglita-
zone has been withdrawn in many countries worldwide, and
due to concerns over its possible association with bladder
cancer, pioglitazone has been suspended in some European
countries.
These safety issues regarding TZDs have raised a number
of questions. Firstly, what are the mechanisms underlying
these unfavorable eﬀects? Is PPARγ still an attractive phar-
macological target to treat metabolic disease? What are the
tools to ﬁnd safe and eﬀective PPARγ ligands? Over the
last years, basic research and clinical studies have provided
many insights into how PPARγ-based therapies could be
optimized.
2. What Arethe Basis of TZDs’ AdverseEvents?
T h r e eT Z D sh a v eb e e na p p r o v e df o rt h et r e a t m e n to f
insulin resistance associated with T2D over the last 15 years:
troglitazone (which was discontinued in 1998), rosiglita-
zone, and pioglitazone (which have been discontinued in
some countries and restricted in others). Although they
are eﬀective agents for the treatment of T2D, their use
is associated with a number of adverse events. Some of
them are considered common to the TZD class of drugs,
whereas others are unique to individual TZDs. The latter
are best characterized by idiosyncratic hepatotoxicity asso-
ciated speciﬁcally with troglitazone [16], which was the
reason for its discontinuance. Well-established class adverse
eﬀects include ﬂuid retention, increased risk of congestive
heart failure, weight gain and bone loss. The mechanisms
underlying some of these unfavorable eﬀects have been
deﬁned, but those of many others remain to be deﬁned, as
is the case of increased risk of myocardial infarction seen
with rosiglitazone treatment [13] or the possible association
between bladder cancer and pioglitazone [14, 15].
2.1. Fluid Retention. TZD treatment is consistently asso-
ciated with body ﬂuid expansion, which is accompanied
by hemodilution, peripheral edema, and the potential to
increase the risk of congestive heart failure [11, 17]. The
mechanisms underlying ﬂuid retention are not completely
deﬁned, although PPARγ action in modulating sodium
transport in the collecting duct (CD) in both animal models
[18, 19] and humans [20] seems to be involved. PPARγ is
mainly expressed in CD [21, 22] and CD-speciﬁc PPARγ
knockout in mice reduces ﬂuid retention induced by TZDs
[18, 19]. Moreover, activation of PPARγ in CD cells results in
increased expression of epithelium sodium channel (ENaC)
[18, 19] and enhances apical localization of the β-subunit
of the ENaC in cortical CD cells [23], which in turn
increase sodium and ﬂuid reabsorption. In addition, TZDs
increase the activity of the ENaC and Na-K-ATPase system,
independent of the increase in ENaC expression [24, 25].
There are also data to suggest that ENaC-independent
mechanisms might be involved, since amiloride, an inhibitor
of ENaC, fails to prevent TZD-induced ﬂuid retention [24,
25]. Accordingly, aquaporin-2 has been also implicated in
this phenomenon [26].
Plasma volume expansion secondary to renal ﬂuid
reabsorption results in increase luminal pressure in the
microvasculature, which in turn leads to a rise in pressure
gradient across the microvessel wall and hence in ﬂuid ﬂux
to the interstitial compartment [3]. This is considered as
the main mechanism of formation of peripheral edema,
although a direct action of TZDs in endothelium cells to
increase vascular permeability, mediated by PPARγ, has also
been implicated [27–29].
In addition to peripheral edema, renal ﬂuid retention
by TZDs is associated with the potential to increase cardiac
load and precipitate or exacerbate congestive heart failure
[30–32]. This has been the rationale to contraindicate TZD
treatment in patients with class III or IV heart failure
according to the criteria of the New York Heart Association
[17]. Despite the propensity to precipitate congestive heart
failure, there has been an intense debate over the possibility
of direct cardiotoxicity of TZDs, especially of rosiglitazone,
as will be discussed later.
2.2. Weight Gain. Increases in body weight are seen with
all TZDs in both animal studies including rodents and
nonrodents [6] and clinical studies [10, 11]. This eﬀect
has been traditionally ascribed to increased adipogenesis
a n dﬂ u i dr e t e n t i o nr e s u l t i n gf r o mP P A R γ activation by
TZDs in adipose tissue and collecting duct cells, respectively.
Moreover, it has been recently suggested that TZDs might
inﬂuence energy balance by activating PPARγ in the central
nervous system (CNS) and inducing increased food intake
[33, 34].
Increased body fat mass has been classically associated
with insulin resistance and cardiovascular disease, and hence
weight gain is considered unfavorable in the treatment of
T2D patients, in whom overweight or obesity is already
frequent. However, increased adipogenesis with TZD treat-
ment is associated with fat redistribution characterized by
an increase in subcutaneous adipose tissue and concomitant
decrease in visceral adipose tissue [35, 36]. Because of the
unfavorable eﬀect of visceral fat on insulin sensitivity, this
redistribution of fat by TZDs is generally considered as
beneﬁcial in spite of increased body adiposity [37].
Despite the correlation between increased insulin sensi-
tivity and adipogenesis and fat redistribution by TZD treat-
ment, the need for increased adipogenesis to the antidiabetic
eﬀect of these drugs has been questioned. A substantial part
of the insulin-sensitizing eﬀect of TZDs has been ascribed toPPAR Research 3
their ability to induce adipocyte expression of adiponectin
and reduce the expression other adipokines, which impair
insulin action in peripheral tissues [2]. In addition, many
PPARγ ligands with partial agonist activity have been shown
to dissociate adipogenesis and weight gain from the insulin
sensitizing eﬀects [38], as will be discussed later.
WeightgainwithTZDtreatmenthasalsobeencorrelated
with increased food intake for some years, at least in
murine models [39]. Only recently, however, their eﬀects on
feeding have been dissociated from PPARγ activation on the
adipose tissue. Complimentary reports by two independent
research groups have suggested that PPARγ action in the
CNS mediates its eﬀects on food intake and energy balance
[33, 34]. Ryan et al. showed that either acute or chronic
activation of PPARγ by TZD treatment or hypothalamic
overexpression of PPARγ, respectively, resulted in hyperpha-
gia, positive energy balance, and weight gain. Conversely,
inhibition of endogenous brain PPARγ action led to the
opposite eﬀects [33]. Lu et al. demonstrated that neuron-
speciﬁc PPARγ knockout mice exhibited reduced food
intake, increased energy expenditure during high-fat diet,
resulting in reduced weight gain. Moreover, these animals
were resistant to rosiglitazone-induced increase in feeding
and weight gain [34].
2.3. Myocardial Infarction and Cardiovascular Mortality.
IncreasedriskofcongestiveheartfailurewithTZDtreatment
has been traditionally associated with the propensity of these
drugs to induce plasma volume expansion and increased
cardiac load. However, the role of PPARγ in the heart has
been controversial. Some animal studies have suggested that
the direct action of PPARγ on the heart could be beneﬁcial,
since TZDs improve cardiac performance [40, 41], decrease
cardiac hypertrophy [42–44], and may also have beneﬁcial
eﬀects on left ventricular remodeling and function after
ischemic injury [45, 46]. Other studies, in contrast, have
suggested that TZDs induce cardiac hypertrophy in rodent
models of diabetes [47, 48], although increased cardiac mass
could not be attributed directly to PPARγ actions on the
heart. Indeed, there are data to suggest that cardiac hyper-
trophy seen with TZDs may involve PPARγ-dependent and
independentpathways,sincecardiomyocyte-speciﬁcPPARγ-
knockout mice were shown to develop cardiac hypertrophy
and treatment of both wild-type and knockout mice with
rosiglitazone also induced cardiac hypertrophy [49].
Clinicalstudiesnotprimarilydesignedtoaddressdeﬁnite
cardiovascular outcomes have also suggested no adverse
eﬀects of TZDs on cardiac performance or even a trend
toward beneﬁcial eﬀects [40, 50]. Despite these potential
favorable eﬀects, in 2007 a meta-analysis indicated a sig-
niﬁcant increased risk for myocardial infarction and car-
diovascular mortality in patients treated with rosiglitazone
[13] and initiated concerns about the drug’s cardiovascular
safety. Since then, there has been no randomized controlled
cardiovascular outcome trial suﬃciently powered to conﬁrm
or refute these data [51–53]. Other meta-analyses conducted
subsequently have either conﬁrmed the initial ﬁndings or
been inconclusive [54, 55], but none has refuted that
rosiglitazone is associated with increased myocardial infarc-
tion risk. Moreover, the meta-analysis published in 2007
was updated in 2010 using alternative analysis to include
trials with no cardiovascular events and conﬁrmed the
previous data that rosiglitazone increases risk for myocardial
infarction [56].
The concerns regarding rosiglitazone’s cardiovascular
safety have raised the question of whether pioglitazone
treatment is associated with a similar risk, since the mech-
anisms underlying increased risk for myocardial infarction
with rosiglitazone have not been deﬁned and it is there-
fore not known whether they are speciﬁc to this drug
or represent a class eﬀect. The Prospective Pioglitazone
Clinical Trial in Macrovascular Events (PROACTIVE trial)
was a large randomized controlled trial designed to address
cardiovascular outcomes that showed a beneﬁt only in
prespeciﬁed endpoints of death, myocardial infarction, and
stroke [30]. It did not show statistically signiﬁcant beneﬁts
in primary outcome, a broad composite of cardiovascular
events.Smallerstudieshavesimilarlyfoundthatpioglitazone
is not associated with increased cardiovascular risk other
than the potential of exacerbation of congestive heart failure
[57–59], whereas others have even suggested cardiovascular
beneﬁt [60].
Collectively, these data have raised two important ques-
tions. Firstly, what are the potential mechanisms underlying
the cardiovascular adverse eﬀects associated with rosigli-
tazone treatment? Further, what explains the diﬀerences
between rosiglitazone and pioglitazone with respect to
cardiovascularhazards?Thesequestionsremainunanswered,
although conceivable mechanisms have been suggested.
Clinical studies have shown that pioglitazone and rosigli-
tazone have diﬀerent eﬀects on lipid proﬁles. Rosiglitazone
treatmentincreaseslow-densitylipoproteincholesterollevels
and triglyceride levels [61], whereas pioglitazone reduces
triglyceride levels and induces greater increases in high-
density lipoprotein cholesterol levels [61]. In addition, the
pattern of modulation of gene expression seems to be
diﬀerent when comparing both TZDs [62–64]. In a murine
model of diabetes, rosiglitazone upregulated the expression
of a matrix metalloproteinase gene in the heart, which
encodes an enzyme implicated in plaque rupture [64].
2.4. Bone Loss and Increased Fracture Risk. Several clinical
studies have linked both rosiglitazone and pioglitazone
treatment to small but signiﬁcant decreases in bone min-
eral density and increased fracture risk [12, 65–71], most
frequently in women. Preclinical in vivo studies have greatly
contributed to elucidate the mechanisms underlying this
unfavorable eﬀect. Treatment of mice with rosiglitazone
suppresses osteoblast diﬀerentiation and increases marrow
adipocytes [72], possibly by activating PPARγ in bone
marrow stromal cells and diverting them from the osteoblast
lineage into the adipocyte lineage [73]. Marrow insulin
growth factor system may also be involved, since it is a
keymodulatorofosteoblastdiﬀerentiationandproliferation,
and activation of PPARγ by rosiglitazone downregulates
some components of this system [74]. Moreover, PPARγ4 PPAR Research
activation in hematopoietic precursors of the monocytic-
macrophage lineage increases osteoclastogenesis and bone
resorption [75].
2.5. Carcinogenesis. Concerns regarding the eﬀect of TZDs
on carcinogenesis are not recent; in 2005, pioglitazone and
ﬁve of six dual PPARα/γ agonists were listed as having
carcinogenic activity in rat bladder, and this has been [76]
the rationale for FDA’s oﬃcial requirement, since 2006, that
2-year rodent carcinogenicity studies with PPAR ligands are
conducted before clinical trials [77] .T h e s ec o n c e r n sh a v e
been intensiﬁed recently, after the publication of observa-
tional clinical studies linking pioglitazone to bladder cancer
risk [14, 15]. In contrast, there have been no preclinical
and clinical data linking PPARα agonist to this type or
cancer [78], neither there have been clinical data linking
rosiglitazonetothistypeofcancer,althoughinarecentstudy
rosiglitazone enhanced bladder tumors in rats pretreated
with a bladder carcinogen [79].
Data from animal studies assessing the eﬀects of PPAR
ligands on tumorigenesis have been controversial. Some
rodent studies have suggested that PPAR ligands may
potentiate the development of diverse types of tumors,
such as transitional cell carcinomas of the urothelium,
hemangiosarcomas, liposarcomas, and sarcomatous tumors
at various sites, whereas other animal studies have indicated
apr ot ecti v eeﬀect.Thesediﬀerenceshavebeenattributedtoa
number of factors, including ligand speciﬁcity (selective acti-
vation of PPARγ versus activation of other PPAR isotypes),
the animal model (rodent versus non-rodent), and cancer
type [3]. This issue is further complicated by data from
in vitro studies suggesting the antiproliferation properties
of PPARγ ligands [80]. Hence, the mechanisms underlying
tumor formation are not established, and although the
tumor types mentioned have been shown to express PPARγ
it still discussed whether these eﬀects are receptor dependent
or -independent.
In particular, urothelium carcinomas have been associ-
ated with pioglitazone and some dual PPARα/δ agonists in
diﬀerent strains of rats (Sprague-Dawley, Fisher, Wistar).
In these models, cellular hypertrophy has been an early
ﬁnding in the bladder urothelium [81] although these eﬀects
have not been established as PPARγ-dependent. In addition,
there are data to suggest that these compounds may result
in the production of cytotoxic urinary solids that could
induce regenerative proliferation in the urothelium in rats
[82]. However, this eﬀe c ti sn o ts e e ni nm i c ea n di sn o t
likely to occur in primates [82]. The signiﬁcance of these
ﬁndings to humans is not clear, but recent observations have
linked pioglitazone to bladder cancer. An interim analysis
of an ongoing 10-year observational study with diabetic
patients has not indicated a signiﬁcant risk of bladder
cancer with pioglitazone treatment for a median duration
of 2 years. However, this risk was signiﬁcantly increased in
patients with longest duration of drug exposure or highest
cumulative drug dose [14]. Further, data from the Adverse
Event Reporting System of the FDA and the French Agency
for the Safety of Health Products indicated a signiﬁcantly
increased risk of bladder cancer with pioglitazone treat-
ment [15]. Pioglitazone was then withdrawn in France
and Germany, and regulatory agencies in other countries
have recommended that the drug should not be used in
patients with active bladder cancer [83]. Notwithstanding,
in a cohort study of 252,467 patients with a followup
of less than 6 years, pioglitazone was not associated with
increased risk of cancer at various sites, including prostate,
female breast, lung/bronchitis, endometrium, colon, pan-
creas, kidney/renal pelvis, rectum, and also of non-Hodgkin
lymphoma and melanoma [84].
3. A Historical Perspective on the Concept of
Safety andEfﬁcacy of PPARγ Ligands
The identiﬁcation of PPARs as key regulators of diverse
aspects of energy homeostasis has made them attractive
pharmacological targets to treat metabolic diseases such as
lipid disorders (drugs targeting PPARα or -δ), T2D (drugs
targeting PPARγ), and obesity (drugs targeting PPARδ).
Initial strategiesof liganddesign aimed todevelop potent
full agonists or ligands acting on diﬀerent PPAR isotypes
to broaden their therapeutic eﬀects. With respect to drugs
targeting PPARγ, the clinical problems observed with the
full agonists TZDs, as well as data from human genetic
studies, animal knockout models, and preclinical and invitro
studieswithligandswithdiﬀerentpharmacologic properties,
have provided important insights into optimization of drug
design strategies.
3.1. PPARγ Ligand Speciﬁcity. The possibility to target
multiple risk factors associated with the metabolic syndrome
by designing drugs with agonistic properties for more than
one isotype of PPAR seemed very promising in the light
of the diverse physiologic roles of this subfamily of nuclear
receptors. Based on this rationale, some dual and pan-
PPAR agonists were developed and some dual PPARα/γ
agonists were evaluated in clinical trials, including muragli-
tazar, tesaglitazar, ragaglitazar, MK-767, and imiglitazar [3].
Failure with these ligands is probably best exempliﬁed by the
ﬁrstPPARα/γ agonist,muraglitazar,whichshowedbeneﬁcial
eﬀects on glucose control and lipid levels of diabetic patients
but was associated with a signiﬁcantly increased risk of
major cardiovascular events in a review of data from phase
2 and 3 clinical trials [85]. Other dual PPARα/γ agonists
evaluated in clinical trials were also discontinued due to
safety concerns [3]. It should be noted, however, that the
reason for development discontinuation of these drugs was
alwayscompoundspeciﬁc,andthereforeitisnotcleariftheir
adverse eﬀects are a class eﬀects or are unrelated to PPAR
activation.
It is also noteworthy that the TZDs pioglitazone and
rosiglitazone, although classically considered selective
PPARγ ligands [4, 86], show weak agonist activity in both
PPARα [87]a n dP P A R δ [87, 88]. In fact, the favorable eﬀects
of pioglitazone on lipid proﬁle accounted for its agonist
properties on PPARα [89, 90]. As discussed before, although
there are no data to attribute developmental failures withPPAR Research 5
dual PPARα/γ agonists to PPAR-dependent mechanisms, the
properties of pioglitazone and rosiglitazone to activate both
isotypes should be carefully considered.
3.2. Full versus Partial PPAR Agonists and Selective PPARγ
Modulation. PPARγ agonists can be grouped into full ago-
nists,classicallyrepresentedbytheTZDs,andpartialagonists
that, at saturating concentrations, result in lower levels of
receptor activation than that of a full agonists. The interest
for compounds with partial agonist activity comes from
better understanding of PPARγ function with data from
animal and human genetic studies and also from studies
with ligands. The minor Ala allele of the human PPARγ2
polymorphism Pro12Ala [91] results in reduced binding
aﬃnity for responsive elements and reduced transcriptional
activity [92, 93]. Clinically, this allele has been associated
with improved insulin sensitivity and reduced risk of T2D
[94–96] and seems to be associated with increased weight
[97]. In addition, mice with germline heterozygous deletion
of the gene encoding PPARγ resulting in reduced PPARγ
activity exhibited increased insulin sensitivity as compared
to wild-type mice [98] and were also resistant to high-fat
diet-induced obesity and insulin resistance [99]. Collectively,
these ﬁndings suggest that milder degrees of PPARγ activa-
tion, rather than its full activation, might be a better strategy
to improve insulin sensitivity while preventing unfavorable
eﬀects of PPARγ action [100]. Based on this concept, partial
PPARγ agonists are viewed as a strategy to maintain the ben-
eﬁts of PPARγ activation and at the same time reduce dose-
dependentsideeﬀectsobservedwiththefullagonists,suchas
weightgainandplasmavolumeexpansion.Indeed,inanimal
models and clinical studies many compounds with weak
agonist activity minimize these unfavorable eﬀects without
loss of the insulin-sensitizing and antidiabetic activity [101].
Due to their ability to discriminate between the actions of
PPARγ indiﬀerenttissues,thesecompoundsarealsoreferred
to as selective PPARγ modulators (SPPARγM) [101].
The molecular basis of the eﬀects of SPPARγM is incom-
pletelyunderstood,buttheireﬀectsprobablystemfromtheir
distinctbindingmodeinthereceptor’sligandbindingpocket
and diﬀerential recruitment of transcriptional cofactors
[102], which can explain the diﬀerent patterns of gene
expression compared to that of full agonists [38]. However,
the pattern of action of these ligands raise an important
question: if the insulin-sensitizing and antidiabetic activity
of PPARγ is closely correlated with their ability to activate
PPARγ-induced transcription [86], why would ligands with
weak agonist activity retain the favorable eﬀects on glucose
homeostasis, comparably to full agonists? Poor understand-
ing of the mechanisms involved in the eﬀects of partial
PPARγ actions may have been one of the reasons for the
reduced interest in these compounds in clinical trials in spite
of their favorable eﬀects in in vitro and preclinical studies.
Ar e c e n ts t u d yb yC h o ie ta l .[ 103]g r e a t l yc o n t r i b u t e dt o
clarifyimportantaspectsofPPARγ action.Thisworkshowed
thatobesity-relatedinﬂammationactivatescyclin-dependent
kinase 5 (Cdk5) in the adipose tissue, which phosphorylates
PPARγ at the serine residue at position 273 and results
in dysregulation of a subset of PPARγ target genes, with
reduced expression of genes with favorable metabolic eﬀects,
notably insulin sensitivity. They also showed that both
full and weak agonists inhibit PPARγ phosphorylation by
Cdk5 comparably. Moreover, this inhibition appears to be
dissociated from classical receptor activation and is well
correlated to the anti-diabetic eﬀects of PPARγ ligands.
These data suggest the rationale behind the action of these
ligands and may not only renew interest for partial PPARγ
ligands that have been already characterized in vitro and
preclinically, but also be viewed as the basis for developing
new PPARγ ligands. It is important to note that these data
also raise important questions. Firstly, how does Cdk5-
mediated phosphorylation of PPARγ lead to dysregulation of
a subset PPARγ target genes? Further, how can the binding
of a ligand to PPARγ inhibit S273 phosphorylation yet
dissociate this eﬀect from general transcriptional activity?
Based on the concept that the transcriptional eﬀects of
PPARγ ligands can be separated from the eﬀects which result
in insulin sensitization, in a subsequent work, Choi et al.
[104] described a novel high-aﬃnity synthetic PPARγ lig-
and (SR1664) completely devoid of classical transcriptional
agonism but with full blocking activity of Cdk5-medidated
phosphorylation. Treatment of wild-type mice with obesity
and insulin resistance induced by high-fat and high-sugar
diet with this ligand resulted in improvement of insulin
sensitivity but in a nonstatistically signiﬁcant reduction in
glucose levels. As expected, in cell-based assays SR1664
antagonized transcriptional activity of PPARγ induced by
rosiglitazone. Collectively, these data might indicate that a
slight degree of partial agonism should be desirable for the
beneﬁts of PPARγ-based therapies.
4. Concluding Remarks
In the light of current knowledge regarding PPARγ action,
optimized ligands would be those with mild agonistic activ-
ity, potent phosphorylation-inhibiting activity, and tissue-
speciﬁc actions. With this proﬁle, it might be possible to
lower the risk of side eﬀects while achieving maximal eﬃcacy
in treating insulin resistance. An important question is
whether it would be cost-eﬀective to search for new ligands
with these features, since there are safe drugs currently
available to treat T2D. The answer is probably yes, since
metformin is the only marketed drug to treat insulin
resistance, an important physiopathological component of
the disease. Moreover, insulin resistance is associated with
conditions other than T2D, such as obesity, cancer, and
cardiovascular disease, and therefore new insulin-sensitizing
agents could potentially have extensive clinical indications.
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